Top Markets
Coin of the day
Accelerate Diagnostics, Inc. Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc.

AXDX
Rangering i aksjer #40437
Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in... Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in solutions for the rapid diagnosis of critical infections, with operations spanning the United States, Europe, and the Middle East. The company's primary offering is the Accelerate Pheno system, an advanced in vitro diagnostic platform. Paired with its dedicated test kit, the Accelerate PhenoTest, this system facilitates quick identification and antimicrobial susceptibility testing (AST) for pathogens responsible for severe or healthcare-associated infections, encompassing both Gram-positive and Gram-negative organisms. The PhenoTest is specifically designed to yield crucial ID and AST results for patients suspected of bacteremia or fungemia – life-threatening conditions marked by high morbidity and mortality risks. Established in 1982, the company initially operated as Accelr8 Technology Corporation before adopting its current name, Accelerate Diagnostics, Inc., in December 2012. Its corporate headquarters are located in Tucson, Arizona.
Aksjekurs
$0.01005
Sist synkronisert: 2025-06-09
Markedsverdi
$146.42K
Endring (1 dag)
-28.21%
Endring (1 år)
0.00%
Land
US
Handel Accelerate Diagnostics, Inc. (AXDX)

Kategori

Inntekter for Accelerate Diagnostics, Inc. (AXDX)
Inntekter i 2026 TTM: 0
Ifølge Accelerate Diagnostics, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Accelerate Diagnostics, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
$1.42B -
US